Injectable therapy should be considered in T2DM patients who have received two or more oral anti-diabetic drugs or non-insulin injectables and have not reached their individualized HbA1c target despite optimized therapy over approximately 3 months, considering adherence, appropriate dosing, and lifestyle interventions. The gene discussed is INS; the disease is type 2 diabetes mellitus.